Clinical Trials
11 trialsNCT01604889 2026-04-21
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
Phase 1/2 Terminated
NCT02298153 2026-04-20
A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma
Incyte Corporation
Phase 1 Terminated
NCT04586244 2025-10-30
Optimus
Incyte Corporation
Phase 2 Terminated
NCT02959437 2025-10-21
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Incyte Corporation
Phase 1/2 Terminated
NCT03347123 2022-02-28
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
Incyte Corporation
Phase 1/2 Terminated
NCT03277352 2021-07-22
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT03361228 2020-05-21
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
Incyte Corporation
Phase 1/2 Terminated
NCT02559492 2019-09-25
Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT03348904 2019-06-13
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Incyte Corporation
Phase 3 Terminated
NCT02575807 2019-04-04
SEASCAPE
Aduro Biotech, Inc.
Phase 1/2 Terminated
NCT01685255 2019-03-11
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
Incyte Corporation
Phase 2 Terminated